Cooperative Agreement 2307164
Award Date
5/1/24
Completion Date
4/30/26
Dollars Obligated
$1M
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Redwood City, CA 94063, USA
Similar Awards
This National Science Foundation (NSF) Cooperative Agreement award under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $1,250,000.00 in funding to Biodevek Inc., a small business located in Boston, MA, to develop a novel sprayable hydrogel sealant for managing gastrointestinal (GI) lesions and bleeding. The project aims to create a minimally invasive, bio-adhesive hydrogel solution that can be applied using an endoscopic delivery system to provide...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $1,000,000 to Theromics Inc., a minority-owned small disadvantaged business, aims to develop a novel protein-based gel to improve the effectiveness and safety of thermal tumor ablation procedures. The project will involve creating a computational model to predict the thermal behavior of the gel, conducting preclinical studies to quantify temperatures, ablation zone size,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) grant of $275,000 awarded to Eugit Therapeutics, Inc. aims to develop a novel targeted therapeutic delivery system for the treatment of inflammatory bowel disease (IBD). The project seeks to create a proof-of-concept platform for identifying agents that can specifically accumulate in diseased tissues within the gastrointestinal tract. By conducting...
This $962,735 cooperative agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships program (CFDA 47.084) supports the development of an enhanced biodegradable tissue adhesive for gastrointestinal surgical wound closure applications by Bezwada Biomedical LLC. The small business will refine a polyurethane-based adhesive formulation and assess its in vivo performance to identify a safe, easy-to-use lead tissue adhesive that can help prevent anastomotic...
The National Science Foundation (NSF) awarded a $275,000 Small Business Innovation Research (SBIR) Phase I project grant to Agil Therapeutics Inc. under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084). This two-year project aims to develop a novel cryoablation system for minimally invasive treatment of type 2 diabetes. The system is designed to deliver a highly controlled and targeted cryogenic agent to the duodenum, with the goal of remodeling the duodenal tissue to...
Karios Technologies LLC, a for-profit organization, received a $274,954 SBIR Phase I grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel, ready-to-use, large volume delivery system for in situ forming biomaterials. The biomaterials are intended to serve as tissue sealants, scar tissue reducers, and vehicles for drug or cell delivery during surgical procedures. The project aims to transfer a proprietary biomaterial...
This SBIR Phase I grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) is for the development of an advanced wound care product to treat diabetic foot ulcers. Therapeutic Bandage Products, Inc. will receive $305,000 to develop a patented microneedle bandage that delivers three therapeutic agents to disinfect the wound, prevent biofilm formation, and activate the immune system. This innovative product has significant...
This $1,000,000 Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a sustained-release, biodegradable drug delivery system using anti-inflammatory nanoparticles and Hedgehog pathway antagonists. The goal is to create a localized treatment for post-traumatic injuries and complications in orthopedic surgery that can improve patient outcomes and reduce societal costs...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) Program (CFDA 47.084) Project Grant award of $275,000 provides funding to Illuminate Therapeutics, Inc. to develop their Light Activated Drug Delivery and Release (LADDR) platform technology. The objective is to improve patient outcomes in the treatment of head and neck and esophageal cancers, which represent a combined market of over $2.34B in 2021 growing at 10.5% annually. The key focus of this SBIR Phase...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Absco Therapeutics, Inc. aims to develop an image-guided intratumoral delivery system for biologic cancer immunotherapies. The project seeks to improve the localized retention, controlled release, and therapeutic efficacy of these biologics within solid tumors, addressing current limitations of rapid drug leakage and systemic toxicity. The anticipated outcomes...